Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Infect Control Hosp Epidemiol ; 45(2): 207-214, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37649167

ABSTRACT

OBJECTIVE: To measure the impact of an automated hand hygiene monitoring system (AHHMS) and an intervention program of complementary strategies on hand hygiene (HH) performance in both acute-care and long-term care (LTC) units. DESIGN: Prospective, nonrandomized, before-and-after intervention study. SETTING: Single Veterans Affairs Medical Center (VAMC), with 2 acute-care units and 6 LTC units. METHODS: An AHHMS that provides group HH performance rates was implemented on 8 units at a VAMC from March 2021 through April 2022. After a 4-week baseline period and 2.5-week washout period, the 52-week intervention period included multiple evidence-based components designed to improve HH compliance. Unit HH performance rates were expressed as the number of dispenses (events) divided by the number of patient room entries and exits (opportunities) × 100. Statistical analysis was performed with a Poisson general additive mixed model. RESULTS: During the 4-week baseline period, the median HH performance rate was 18.6 (95% CI, 16.5-21.0) for all 8 units. During the intervention period, the median HH rate increased to 21.6 (95% CI, 19.1-24.4; P < .0001), and during the last 4 weeks of the intervention period (exactly 1 year after baseline), the 8 units exhibited a median HH rate of 25.1 (95% CI, 22.2-28.4; P < .0001). The median HH rate increased from 17.5 to 20.0 (P < .0001) in LTC units and from 22.9 to 27.2 (P < .0001) in acute-care units. CONCLUSIONS: The intervention was associated with increased HH performance rates for all units. The performance of acute-care units was consistently higher than LTC units, which have more visitors and more mobile veterans.


Subject(s)
Cross Infection , Hand Hygiene , Veterans , Humans , Cross Infection/prevention & control , Health Personnel , Infection Control , Prospective Studies
2.
Urol Case Rep ; 48: 102416, 2023 May.
Article in English | MEDLINE | ID: mdl-37215057

ABSTRACT

60-year-old man with known chronic urinary retention (CUR) managed with clean intermittent catheterization (CIC); He presented with difficulty with CIC. A KUB revealed 13 cm in conglomeration bladder stones. Routine preoperative bloodwork revealed calcium >12 and a subsequent PTH was also elevated. Osteoporosis was confirmed on DEXA. Sestamibi parathyroid scan had increased uptake within one parathyroid gland. The patient underwent open suprapubic 92 gm prostatectomy with evacuation of 254 gm calcium phosphate bladder stones; this was followed by removal of the offending parathyroid gland. On follow up, the patient was voiding well with normalization of other symptoms related to hyperparathyroidism.

3.
Clin Infect Dis ; 76(1): 103-112, 2023 01 06.
Article in English | MEDLINE | ID: mdl-35676823

ABSTRACT

BACKGROUND: Nontuberculous Mycobacterium infections, particularly Mycobacterium abscessus, are increasingly common among patients with cystic fibrosis and chronic bronchiectatic lung diseases. Treatment is challenging due to intrinsic antibiotic resistance. Bacteriophage therapy represents a potentially novel approach. Relatively few active lytic phages are available and there is great variation in phage susceptibilities among M. abscessus isolates, requiring personalized phage identification. METHODS: Mycobacterium isolates from 200 culture-positive patients with symptomatic disease were screened for phage susceptibilities. One or more lytic phages were identified for 55 isolates. Phages were administered intravenously, by aerosolization, or both to 20 patients on a compassionate use basis and patients were monitored for adverse reactions, clinical and microbiologic responses, the emergence of phage resistance, and phage neutralization in serum, sputum, or bronchoalveolar lavage fluid. RESULTS: No adverse reactions attributed to therapy were seen in any patient regardless of the pathogen, phages administered, or the route of delivery. Favorable clinical or microbiological responses were observed in 11 patients. Neutralizing antibodies were identified in serum after initiation of phage delivery intravenously in 8 patients, potentially contributing to lack of treatment response in 4 cases, but were not consistently associated with unfavorable responses in others. Eleven patients were treated with only a single phage, and no phage resistance was observed in any of these. CONCLUSIONS: Phage treatment of Mycobacterium infections is challenging due to the limited repertoire of therapeutically useful phages, but favorable clinical outcomes in patients lacking any other treatment options support continued development of adjunctive phage therapy for some mycobacterial infections.


Subject(s)
Bacteriophages , Cystic Fibrosis , Mycobacterium Infections, Nontuberculous , Mycobacterium , Phage Therapy , Humans , Compassionate Use Trials , Pharmaceutical Preparations , Mycobacterium Infections, Nontuberculous/microbiology , Cystic Fibrosis/microbiology , Anti-Bacterial Agents/therapeutic use
4.
Am J Med Sci ; 365(3): 294-301, 2023 03.
Article in English | MEDLINE | ID: mdl-36473546

ABSTRACT

Xanthogranulomatous pyelonephritis (XGP) is a rare variant of chronic pyelonephritis, occurring in the setting of obstructive uropathy and recurrent urinary tract infections (UTIs). It is difficult to diagnose as it can be asymptomatic until late-stage disease. Localized symptoms such as flank pain and dysuria may be attributed to nephrolithiasis or UTIs without prompting need for further workup. Extrarenal manifestations, most notably fistula formation, may present distal to the kidney and not be readily attributed to a renal pathology. The only known definitive therapy is nephrectomy. A delay in diagnosis can lead to fulminant complications or a more technically difficult nephrectomy. We present three cases of XGP, which serve to highlight the possibility of earlier diagnosis and resultant management options, including the potential for nephron-saving strategies. Early clinical and radiologic suspicion through awareness of risk factors may play an important role in preventing disease progression, avoiding late-stage complications, and improving treatment outcomes.


Subject(s)
Pyelonephritis, Xanthogranulomatous , Urinary Tract Infections , Humans , Pyelonephritis, Xanthogranulomatous/diagnosis , Pyelonephritis, Xanthogranulomatous/surgery , Kidney/pathology , Nephrectomy , Treatment Outcome
5.
Am J Case Rep ; 23: e936441, 2022 Jul 13.
Article in English | MEDLINE | ID: mdl-35830369

ABSTRACT

BACKGROUND Pneumoscrotum is a rare clinical occurrence in which air accumulates in the scrotum. The origin of air is primarily from trauma, but spontaneous pneumoscrotum can develop from gastrointestinal or pulmonary sources. Physical examination of pneumoscrotum typically includes crepitus of the perineal region and scrotal swelling and associated findings depending on the origin of the free air. However, pneumoscrotum in the setting of a scrotal wound, which allows air to pass freely outside the body, has not been previously documented in the literature. CASE REPORT A 72-year-old man who recently underwent a scrotal incision and drainage for recurrent epididymitis presented to a local emergency room with chief concerns of "whistling scrotum" and dyspnea. The chest CT revealed bilateral pneumothoraces, pneumomediastinum, and excessive subcutaneous emphysema throughout his abdomen, perineum, and scrotum. His scrotum had a dehiscent wound without any gross edema or air trapping contained within the scrotum. He received bilateral chest tubes and subcutaneous air drains with complete resolution of his pneumothoraces. The pneumoscrotum and associated subcutaneous emphysema of the perineum and thighs resolved after a prolonged period, and necessitated additional scrotal surgery. CONCLUSIONS Prompt evaluation for source control is necessary with pneumoscrotum, as the source likely requires immediate stabilization or surgical intervention. This case report describes a unique presentation of a common entity (pneumothorax) within pulmonology/critical care in a patient with an open scrotal wound from a recent scrotal procedure, which allowed the air to escape from his abdominal compartment, and resulted in his "scrotal whistling." It is unclear how the air passing through the scrotum affected the patient's presentation, such as allowing more air to build up in the subcutaneous tissues versus developing critical illness.


Subject(s)
Genital Diseases, Male , Mediastinal Emphysema , Pneumothorax , Singing , Subcutaneous Emphysema , Aged , Edema , Genital Diseases, Male/complications , Humans , Male , Mediastinal Emphysema/complications , Mediastinal Emphysema/etiology , Pneumothorax/etiology , Scrotum , Subcutaneous Emphysema/etiology
6.
Clin Infect Dis ; 75(9): 1641-1644, 2022 10 29.
Article in English | MEDLINE | ID: mdl-35510938

ABSTRACT

A patient with end-stage renal disease received 2 doses of dalbavancin for methicillin-resistant Staphylococcus aureus (MRSA) arteriovenous fistula infection and presented 5 weeks later with infective endocarditis secondary to vancomycin, daptomycin, and dalbavancin nonsusceptible MRSA. Resistance was associated with walK and scrA mutations, reduced long-chain lipid content, and reduced membrane fluidity.


Subject(s)
Daptomycin , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections , Humans , Vancomycin/pharmacology , Vancomycin/therapeutic use , Daptomycin/pharmacology , Daptomycin/therapeutic use , Staphylococcus aureus , Methicillin-Resistant Staphylococcus aureus/genetics , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Teicoplanin/pharmacology , Teicoplanin/therapeutic use , Staphylococcal Infections/drug therapy , Microbial Sensitivity Tests
7.
J Infect Prev ; 22(5): 186-193, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34659456

ABSTRACT

BACKGROUND: Central line-associated bloodstream infection (CLABSI) is a preventable medical condition that results in increased patient morbidity and mortality. We describe the impact of various quality improvement interventions on the incidence of CLABSI in an 848-bed community teaching hospital from 1 January 2013 to 31 December 2017. AIM: To reduce CLABSI rates after implementation of a comprehensive central line insertion and maintenance bundle. METHODS: A comprehensive bundle of interventions was implemented incorporating the standard US Centers for Disease Control and Prevention bundle with additional measures such as root-cause analysis of all CLABSI cases, use of passive disinfection caps on vascular access ports, standardisation of weekly central venous catheter (CVC) site dressing changes, and use of antithrombotic and antimicrobial-coated CVCs with fewer lumens. A retrospective study evaluated CLABSI rates and time of CLABSI onset after CVC placement in both intensive care unit (ICU) and non-ICU settings. RESULTS: The annual number of CLABSI cases declined 68% (34 to 11 patients) from 2013 to 2017. There was a 30% decline in CVC days from years 2014 to 2017. Over the same period, CLABSI cases per 1000 CVC days decreased from 0.624 to 0.362: a 42% decline. CONCLUSION: Following the implementation of a comprehensive bundle of interventions for CVC insertion and maintenance, we found a reduction in rates of CLABSI.

8.
Case Rep Infect Dis ; 2021: 8865339, 2021.
Article in English | MEDLINE | ID: mdl-33777466

ABSTRACT

We describe a case of gonococcal spontaneous bacterial peritonitis (SBP) in a 48-year-old sexually active female with alcoholic cirrhosis and chronic hepatitis B. She was admitted with fever, abdominal pain and distension without dysuria, dyspareunia, or vaginal discharge. On exam, she was icteric with features of sepsis and tense ascites. She underwent paracentesis. The ascitic fluid analysis revealed a neutrophil count of 1,050/µL, and culture grew Neisseria gonorrhoeae. Pelvic examination findings were negative for pelvic inflammatory disease; however, an endocervical swab was positive for N. gonorrhoeae by PCR. She was diagnosed with spontaneous bacterial peritonitis secondary to N. gonorrhoeae and was successfully treated with a seven-day course of IV ceftriaxone. N. gonorrhoeae spontaneous bacterial peritonitis is an extremely rare entity reported only twice despite the high prevalence of gonorrhoeae in the general population. We hypothesize that gonococcal SBP may be frequently undiagnosed since it responds to empiric antibiotics used to treat SBP. It is important for the clinician to be aware of gonococcus as a rare but potential pathogen in SBP. Future studies are needed to determine if routine gonococcal screening in SBP cases would be of clinical utility.

9.
Surg Infect (Larchmt) ; 22(4): 409-414, 2021 May.
Article in English | MEDLINE | ID: mdl-32783694

ABSTRACT

Background: Surgical site infections (SSI) are multifaceted. Pre-operative, intra-operative, and post-operative factors influence the risk of developing an infection. Our objective was to evaluate the effectiveness of an infection risk-stratification checklist, utilizing known SSI risk factors, and a tailored surgical protocol for SSI prevention in women undergoing cesarean delivery. Patients and Methods: A prospective project to reduce SSI was conducted for women undergoing cesarean delivery on the resident staff service at a midwestern, urban tertiary care hospital. Patients were categorized according to an SSI risk-stratification checklist as high risk or low risk. The low-risk group received the local standard of care (single prophylactic dose of pre-operative intravenous antibiotics and a standard pressure dressing). In the high-risk group, prophylactic antibiotic agents were given pre-operatively and continued for the first 24 hours post-operatively. Additionally, patients at high risk received an absorbent dressing (Mepilex Ag®; Mölnlycke Health Care AB, Gothenburg, Sweden) that was applied in the operating room and worn for one week. Results: The overall rate of SSIs decreased from 6.1% (pre-study rate) to 1.4% after initiation of the protocol, a 77% reduction (p < 0.001). The low- and high-risk groups did not differ in infection rate (0% and 1.4%, respectively; p < 0.59). Both deep incisional and organ/space SSIs decreased after initiation of the protocol (91% and 62% decrease, respectively). Conclusion: Stratifying patients into high- and low-risk groups with tailored peri-operative management strategies reduced overall SSIs. The protocol incorporates known risk factors for SSI in a surgical procedure with high rates of SSI. This approach offers a structured method that can be adopted by other hospital systems for SSI prevention in patients undergoing cesarean delivery.


Subject(s)
Cesarean Section , Surgical Wound Infection , Anti-Bacterial Agents/therapeutic use , Cesarean Section/adverse effects , Female , Humans , Pregnancy , Prospective Studies , Risk Factors , Surgical Wound Infection/drug therapy , Surgical Wound Infection/epidemiology , Surgical Wound Infection/prevention & control
10.
Case Rep Infect Dis ; 2018: 1749691, 2018.
Article in English | MEDLINE | ID: mdl-29666726

ABSTRACT

We describe a rare infection with Nocardia spp. (N. pseudobrasiliensis species identification based on high-performance liquid chromatography analysis) in a 68-year-old renal transplant recipient. He presented with pneumonia complicated by hypoxic respiratory failure. He was allergic to sulphonamides. He was initially successfully treated with linezolid. However, he suffered severe sensory neuropathy after 4 months of therapy, necessitating linezolid cessation and completion of treatment with azithromycin. He had clinical and radiological resolution of his pneumonia and was disease free at subsequent follow-up 4 years later. This case highlights the need for alternative therapies for nocardiosis for patients that cannot be treated with sulphonamides due to allergies or/and infection with multidrug-resistant pathogens. It also illustrates the treatment limiting side effects of long-term therapy with linezolid.

12.
Article in English | MEDLINE | ID: mdl-27442378

ABSTRACT

Hepatitis C virus (HCV), the major etiologic agent of "non-A, non-B hepatitis" was discovered 26 years ago. Even before its discovery, interferon-α (IFN) was already being used for treatment of this infection. The next two decades saw a series of incremental improvements of the IFN therapies by extending the duration of therapy, using IFN in combination with oral ribavirin, using pegylated IFN with ribavirin, and most recently adding oral compounds that inhibit the HCV replication (directly acting antivirals - DAAs) to that regimen. DAAs target multiple steps in the HCV life cycle and are now used in combination to treat HCV infection without the need of IFN. These IFN-free, oral DAAs regimens are highly efficacious, have minimal toxicity and are given for short duration. Approved DAAs can cure more then 90% of persons with chronic HCV infection, thereby reducing the risk of death from cirrhosis and hepatocellular carcinoma. However, these drugs are very expensive, and currently their exorbitant cost significantly restricts the access to this therapy for many HCV infected patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/drug effects , Hepatitis C/drug therapy , Antiviral Agents/adverse effects , Antiviral Agents/economics , Drug Costs , Drug Resistance, Viral , Drug Therapy, Combination , Health Services Accessibility/economics , Hepacivirus/pathogenicity , Hepatitis C/diagnosis , Hepatitis C/economics , Hepatitis C/virology , Humans , Treatment Outcome
13.
Case Rep Nephrol ; 2014: 130624, 2014.
Article in English | MEDLINE | ID: mdl-25161783

ABSTRACT

We report a case of a 72-year-old diabetic male who developed infection-related glomerulonephritis (IRGN) in the setting of severe Staphylococcus epidermidis infection. He required renal replacement therapy for 6 weeks, but had full recovery of his kidney function with aggressive treatment of the infection. While this pathogen has been previously implicated as the cause of shunt nephritis, it is exceptionally rare to be associated with IRGN in the absence of a shunt or other prosthetic material.

14.
Heart Lung ; 43(4): 338-40, 2014.
Article in English | MEDLINE | ID: mdl-24751340

ABSTRACT

We present a case of a 35-year-old male with history of intravenous heroin use, who presented with acute limb ischemia and was found to have Candida lusitaniae endocarditis. After an urgent intervention to salvage the right lower extremity, successful outcome of his infection was achieved by a combined surgical and antifungal treatment.


Subject(s)
Candidiasis/complications , Endocarditis/complications , Ischemia/etiology , Leg/blood supply , Adult , Antifungal Agents , Aortic Valve , Candida , Endocarditis/diagnosis , Endocarditis/microbiology , Humans , Male , Substance Abuse, Intravenous/complications
15.
Infect Control Hosp Epidemiol ; 35(4): 437-9, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24602953

ABSTRACT

Carbapenem-resistant Enterobacteriaceae (CRE) infections are increasing and are associated with considerable morbidity and mortality. Members of the Emerging Infections Network treating CRE encountered difficulties in obtaining laboratory results and struggled with limited treatment options. In addition, many treated patients experienced an alarming degree of drug toxicity from CRE therapies.


Subject(s)
Carbapenems/therapeutic use , Drug Resistance, Bacterial , Enterobacteriaceae Infections/drug therapy , Enterobacteriaceae/drug effects , Adult , Carbapenems/pharmacology , Female , Humans , Male , Microbial Sensitivity Tests , Surveys and Questionnaires
16.
Int J Antimicrob Agents ; 42(5): 450-5, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23993067

ABSTRACT

Data regarding ceftaroline use for meticillin-resistant Staphylococcus aureus bacteraemia (MRSAB) are lacking. Here we review the outcomes of 31 patients with MRSAB treated with ceftaroline, including 9 patients with endocarditis. Clinical success was observed in 23 patients (74.2%). Adverse events associated with prolonged therapy were rare and included eosinophilic pneumonia, rash and diarrhoea. We conclude that ceftaroline can be used for MRSAB.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacteremia/drug therapy , Cephalosporins/therapeutic use , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/drug therapy , Adolescent , Adult , Aged , Aged, 80 and over , Bacteremia/microbiology , Drug-Related Side Effects and Adverse Reactions/epidemiology , Drug-Related Side Effects and Adverse Reactions/pathology , Female , Humans , Male , Middle Aged , Staphylococcal Infections/microbiology , Treatment Outcome , Young Adult , Ceftaroline
17.
Pharmacotherapy ; 33(7): e166-9, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23649990

ABSTRACT

We present a case of eosinophilic pneumonia due to ceftaroline used for the treatment of methicillin-resistant Staphylococcus aureus bacteremia associated with a postoperative spinal infection. Our patient developed shortness of breath and hypoxemia on the fifth week of ceftaroline therapy. Chest imaging disclosed diffuse bilateral infiltrates. Laboratory abnormalities included peripheral eosinophilia and eosinophilic predominant bronchoalveolar lavage fluid. The combination of ceftaroline discontinuation plus initiation of steroid treatment resulted in complete resolution of signs, symptoms, and radiologic abnormalities. We speculate about possible mechanisms underlying this adverse event and diagnostic criteria for drug-induced eosinophilic pneumonia.


Subject(s)
Anti-Bacterial Agents/adverse effects , Cephalosporins/adverse effects , Pulmonary Eosinophilia/chemically induced , Anti-Bacterial Agents/therapeutic use , Bronchoalveolar Lavage Fluid/chemistry , Cephalosporins/therapeutic use , Glucocorticoids/therapeutic use , Humans , Male , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Pulmonary Eosinophilia/drug therapy , Staphylococcal Infections/drug therapy , Ceftaroline
18.
J Cyst Fibros ; 12(5): 530-1, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23313410

ABSTRACT

We report on an adult with cystic fibrosis (ΔF508/G551D) with severe lung disease (forced expiratory volume (FEV1) in one second 24% predicted) who was admitted for a pulmonary exacerbation. He was managed with maximal medical therapy, but did not have significant improvement until after he was started on ivacaftor on hospital day 15. He subsequently had significant improvement in lung function with normalization of hypercarbia, oxygen saturation on room air, and increase in FEV1 to 36% predicted. Prior to use of ivacaftor he was being assessed for a lung transplant. However, after ivacaftor therapy for 6 months, he is no longer considering this treatment modality due to his improvement of lung function and functional status.


Subject(s)
Aminophenols/therapeutic use , Cystic Fibrosis/complications , Lung Diseases/drug therapy , Lung Diseases/etiology , Quinolones/therapeutic use , Adult , Cystic Fibrosis/physiopathology , Forced Expiratory Volume , Humans , Lung Diseases/physiopathology , Male , Severity of Illness Index
SELECTION OF CITATIONS
SEARCH DETAIL
...